You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

Authors

  • Johannes Laengle Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Julijan Kabiljo Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Leah Hunter Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Jakob Homola Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Sophie Prodinger Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Gerda Egger Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria Department of Pathology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  • Michael Bergmann Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Vienna, Austria PubMed articlesGoogle scholar articles
  1. Correspondence to Michael Bergmann; michael.bergmann{at}meduniwien.ac.at
View Full Text

Citation

Laengle J, Kabiljo J, Hunter L, et al
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
Journal for ImmunoTherapy of Cancer 2020;8:e000195. doi: 10.1136/jitc-2019-000195

Publication history

  • Accepted November 1, 2019
  • First published January 2, 2020.
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.